Company / Working Capital
Myriad Genetics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$198.8M
FY2025
5-year range
$133.9M / $280.5M
FY2021-FY2025
Trend
+48.5%
vs FY2024
Sector context
#171 of 213
Health Care
What the data says
Myriad Genetics, Inc.'s working capital of $199M is lower than 80% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $84M in FY2017 to $281M in FY2021.
Based on SEC 10-K filings.
$199M in FY2025 with a 5-year CAGR of -4.0%.
Improved from $158M to $199M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +13.1%
- 5-Year CAGR
- -4.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 213This company $198.8M Sector average $934.6M
▼
-78.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.0%, indicating a declining trend.
- In FY2025, working capital increased 48.5% year-over-year.
- Ranks #171 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $198.8M | +48.5% |
| FY2024 | $133.9M | -15.1% |
| FY2023 | $157.7M | +14.8% |
| FY2022 | $137.4M | -51.0% |
| FY2021 | $280.5M | +15.2% |
| FY2020 | $243.5M | +5.5% |
| FY2019 | $230.8M | +2.4% |
| FY2018 | $225.4M | +167.7% |
| FY2017 | $84.2M | -65.2% |
| FY2016 | $242.2M | +12.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026